Esperion Therapeutics, Inc. (ESPR)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 01:00PM EST
After hours:
| Previous close | 6.75 |
| Open | 6.73 |
| Bid | 6.87 x 1200 |
| Ask | 7.32 x 1000 |
| Day's range | 6.60 - 6.88 |
| 52-week range | 3.28 - 9.13 |
| Volume | |
| Avg. volume | 1,109,239 |
| Market cap | 505.47M |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.24 |
| Earnings date | 20 Feb 2023 - 24 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.27 |
- Zacks
Xeris (XERS), Horizon to Develop Ready-to-Use Teprotumumab
Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.
- Simply Wall St.
Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) latest 9.4% decline adds to one-year losses, institutional investors may consider drastic measures
To get a sense of who is truly in control of Esperion Therapeutics, Inc. ( NASDAQ:ESPR ), it is important to understand...
- Zacks
ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug
ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.
© 2022 Yahoo. All rights reserved.
